Multiple myeloma (MM) is still incurable B-cell malignancy affecting more than 14,000 Americans annually. Myeloma tumor cells can survive even the most aggressive treatment available today, leading to disease relapses. The long-term goal of this project is to develop more effective cytostatic therapies to eradicate myeloma cells. We recentiy made a novel and exciting discovery that anti-p2-microglobulin (P2M) monoclonal antibodies (mAbs) had strong apoptotic activity in both established myeloma cell lines and primary myeloma cells from patients. The mAbs selectively target and kill myeloma cells in coculture with normal hematopoietic cells without damaging normal blood cells, including CD34+ stem cells. Anti-p2M mAbinduced apoptosis in myeloma cells were not blocked by soluble p2M (10-100 ng/mL, 3- to 30-fold higher than that in most MM patients, which are about 3 jag/mL), IL-6, or other myeloma growth and survival factors. The mAbs induced cell death via inhibiting P13K/Akt and ERK, activating JNK, and compromising mitochondrial integrity, leading to cytochrome c release and activation of a caspase-9-dependent cascade. Furthermore, the mAbs were also active and therapeutic in vivo in xenograft mouse models of myeloma. Thus, we hypothesize that anti-p2M mAbs may be used as therapeutic agents to treat patients with MM. This hypothesis will be tested by the following aims.
Aim 1 will examine the mechanisms of anti-p2M mAbinduced apoptosis in myeloma cells. Using normal plasma or B cells as controls, we will define the role of surface MHC class I and class l-like molecules in these responses, and examine surface proteins binding to, the downstream kinases, and intracellular signaling and apoptosis pathways induced by anti-p2M mAbs.
Aim 2 will utilize immune effector cells or molecules to enhance the efficacy of anti-p2M mAbs, Aim 3 will develop strategies to enhance the efficacy of anti-p2M mAbs to induce apoptosis in myeloma cells by combining with novel antimyeloma agents, and Aim 4 will perform pre-clinical and clinical studies to examine the safety and toxicity profiles of the mAbs.

Public Health Relevance

These novel studies may lead to the development of anti-p2M mAbs as the first clinically useful and effective therapeutic mAbs for treating MM and potentially other malignancies that express surface p2M and MHC class I molecules.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Glitza, Isabella C; Lu, Gary; Shah, Rupin et al. (2015) Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 56:602-7
Wen, Jianguo; Tao, Wenjing; Kuiatse, Isere et al. (2015) Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136:991-1002
Hong, Bangxing; Li, Haiyan; Zhang, Mingjun et al. (2015) p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer 136:34-43
Shi, Qiuling; Wang, Xin Shelley; Li, Guojun et al. (2015) Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121:1138-46
Wang, Xin Shelley; Shi, Qiuling; Williams, Loretta A et al. (2015) Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 56:1335-41
Parmar, S; Kongtim, P; Champlin, R et al. (2014) Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49:1036-41
Chen, Zheng; Orlowski, Robert Z; Wang, Michael et al. (2014) Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123:2204-8
San-Miguel, Jesús; Bladé, Joan; Shpilberg, Ofer et al. (2014) Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123:4136-42
Srkalovic, Gordan; Hussein, Mohamad A; Hoering, Antje et al. (2014) A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med 3:1275-83
Ocio, Enrique M; Mitsiades, Constantine S; Orlowski, Robert Z et al. (2014) Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7:127-41

Showing the most recent 10 out of 79 publications